Antibody-Based Treatment of Acute Myeloid Leukemia.

about

Gene-modified NK-92MI cells expressing a chimeric CD16-BB-ζ or CD64-BB-ζ receptor exhibit enhanced cancer-killing ability in combination with therapeutic antibody.

P2860

Q33913839-BB6344B8-87DB-4EB8-9F6E-6973C754800F

P2860

Antibody-Based Treatment of Acute Myeloid Leukemia.

Item

http://www.wikidata.org/entity/Q38979277

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Antibody-Based Treatment of Acute Myeloid Leukemia.

@en

type

Item

label

Antibody-Based Treatment of Acute Myeloid Leukemia.

@en

prefLabel

Antibody-Based Treatment of Acute Myeloid Leukemia.

@en

P1476

Antibody-Based Treatment of Acute Myeloid Leukemia.

@en

P2093

Eric J Feldman

http://www.w3.org/2001/XMLSchema#string

Phillip M Garfin

http://www.w3.org/2001/XMLSchema#string

P2860

Update on rational targeted therapy in AML

Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell

The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells

Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation

Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse

Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation

Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells

P2888

s11899-016-0349-7

P304

545-552

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11899-016-0349-7

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-10-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1043515422

http://www.w3.org/2001/XMLSchema#string

P698

27734262

http://www.w3.org/2001/XMLSchema#string

Antibody-Based Treatment of Acute Myeloid Leukemia.

about

P2860

P2860

Antibody-Based Treatment of Acute Myeloid Leukemia.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698